FDA Clearance Tracker · P120008
ABBOTT ARCHITECT AFP ASSAY
Last checked: Nov 20, 2026Latest source record: Nov 28, 2012 (this decision)Source: openFDAMethods & limitations
Decided
Nov 28, 2012
Approved
Time to decision
211 days
Received May 1, 2012. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P120008
- Device name
- ABBOTT ARCHITECT AFP ASSAY
- Applicant
- Abbott Laboratories
- Applicant location
- Abbott Park, IL
- Received
- May 1, 2012
- Decided
- Nov 28, 2012
- Decision
- Approved
- Supplements
- 32 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE ARCHITECT AFP ASSAY, ARCHITECT AFP CALIBRATORS AND ARCHITECT AFP CONTROLS. THIS DEVICE IS INDICATED FOR:THE ARCHITECT AFP ASSAY IS A CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) FOR THE QUANTITATIVE DETERMINATION OF ALPHA-FETOPROTEIN (AFP) IN:1) HUMAN SERUM OR PLASMA TO AID IN MONITORING DISEASE PROGRESSION DURING THE COURSE OF DISEASE AND TREATMENT OF PATIENTS WITH NONSEMINOMATOUS TESTICULAR CANCER; AND 2) HUMAN SERUM, PLASMA, AND AMNIOTIC FLUID AT 15 TO 21 WEEKS GESTATION TO AID IN THE DETECTION OF FETAL OPEN NEURAL TUBE DEFECTS (NTD). TEST RESULTS WHEN USED IN CONJUNCTION WITH ULTRASONOGRAPHY OR AMNIOGRAPHY ARE A SAFE AND EFFECTIVE AID IN THE DETECTION OF FETAL OPEN NTD. THE ARCHITECT AFP CALIBRATORS ARE FOR THE CALIBRATION OF THE ARCHITECT I SYSTEM WHEN USED FOR THE QUANTITATIVE DETERMINATION OF ALPHA-FETOPROTEIN (AFP) IN HUMAN SERUM, PLASMA, AND AMNIOTIC FLUID. THE PERFORMANCE OF THE ARCHITECT AFP CALIBRATORS HAS NOT BEEN ESTABLISHED WITH ANY OTHER AFP ASSAYS. THE ARCHITECT AFP CONTROLS ARE FOR THE ESTIMATION OF TEST PRECISION AND THE DETECTION OF SYSTEMATIC ANALYTICAL DEVIATIONS OF THE ARCHITECT I SYSTEM WHEN USED FOR THE QUANTITATIVE DETERMINATION OF ALPHA-FETOPROTEIN (AFP) IN HUMAN SERUM, PLASMA, AND AMNIOTIC FLUID. THE PERFORMANCE OF THE ARCHITECT AFP CONTROLS HAS NOT BEEN ESTABLISHED WITH ANY OTHER AFP ASSAYS.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LOK. The earliest in FDA's data is P820060, decided Jun 21, 1983.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Abbott Laboratories
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Anti-HCV Next510(k)
K262156 · Decided Sep 23, 2026 · 89 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.